Research advances in circulating miRNAs for diagnosis of hepatobiliary diseases

Peng XiaoFang; Liu HaiYing

doi:10.3969/j.issn.1001-5256.2014.09.032

Issue 9

Sep. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(9): 965-968

PDF( 1330 KB)

Research advances in circulating miRNAs for diagnosis of hepatobiliary diseases

DOI: 10.3969/j.issn.1001-5256.2014.09.032

Clinical Laboratory, Guangzhou Women and Children's Medical Center Affiliated to Guangzhou Medical University

Research funding:

Received Date: 2013-11-08
Published Date: 2014-09-20

Abstract

Abstract

MicroRNAs ( miRNAs) are involved in the pathological and physiological process of life activities, and some of them exist stably and abundantly in serum, plasma, and other body fluids. Previous studies have indicated that there are significant differences in the expression patterns of circulating miRNAs between patients with viral hepatitis, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, drug- induced hepatitis, and other hepatobiliary diseases at different disease stages. Among these circulating miRNAs, some can act as novel noninvasive biomarkers for the early diagnosis, disease progression, and prognostic evaluation of related diseases. The latest research advances in circulating miRNAs for the diagnosis of hepatobiliary diseases are reviewed.
- liver diseases,
- biliary tract diseases,
- microRNAs,
- diagnosis,
- review

FullText(HTML)

References(28)

References

[1]MURAKAMI Y, TOYODA H, TANAHASHI T, et al.Comprehensive miRNA expression analysis in peripheral blood can diagnose liver disease[J].PLoS One, 2012, 7 (10) :e48366.

[2]LI C, WAN MB, WANG HF.Research progress on microRNA in the HBV-related liver disease[J].Chin J Gastroenterol Hepatol, 2010, 19 (8) :2371-2373. (in Chinese) 李晨, 万谟彬, 王慧芬.microRNA在HBV相关肝病中的研究进展[J].胃肠病学和肝病学杂, 2010, 19 (8) :2371-2373.

[3]JI F, YANG B, PENG X, et al.Circulating microRNAs in hepatitis B virus-infected patients[J].J Viral Hepat, 2011, 18 (7) :e242-e251.

[4] QIU L, FAN H, JIN W, et al.miR-122-induced down-regulation of HO-1 negatively affects miR-122-mediated suppression of HBV[J].Biochem Biophys Res Commun, 2010, 398 (4) :771-777.

[5]SHWETHA S, GOUTHAMCHANDRA K, CHANDRA M, et al.Circulating miRNA profile in HCV infected serum:novel insight into pathogenesis[J].Sci Rep, 2013, 3:1555.

[6]ARZUMANYAN A, REIS HM, FEITELSON MA.Pathogenic mechanism in HBV and HCV-associated hepato-cellular carcinom[J]Nat Rev Cancer, 2013, 13 (2) :123-135.

[7] BALA S, TILAHUN Y, TAHA O, et al.Increased microRNA-155 expression in the serum and periheral monocytes in chronic HCV infection[J].J Transl Med, 2012, 10:151.

[8] XU MD, LI WYQ, YU HY.Research on microRNA in liver disease and hepatic fibrosis[J].Chin J Pothol, 2011, 40 (1) :65-67. (in Chinese) 许蜜蝶, 利瓦伊卿, 余宏宇.MicroRNA与肝病及肝纤维化相关研究[J].中华病理学志, 2011, 40 (1) :65-67.

[9]LI BB, MING J, CHEN DG, et al.Recent progress in understanding the role of microRNAs in hepatic stellate cell biology and liver fibrosis pathogenesis[J].J Clin Hepatol, 2013, 29 (5) :380-388. (in Chinese) 李彬彬, 明健, 陈大贵, 等.MicroRNA在肝纤维化进程中的作用[J].临床肝胆病杂志, 2013, 29 (5) :380-388.

[10]WAIDMANN O, BRUNNER F, ZEUZEM S, et al.Serum MicroRNA-122 predicts survival in patients with liver cirrhosis[J].PLoS One, 2012, 7 (9) :e45652.

[11]CHEN YJ, ZHU JM, WU H, et al.Circulating microRNAs as a fingerprint for liver cirrhosis[J].PLoS One, 2013, 8 (6) :e66577.

[12]SHRIVASVATA S, PETRONE J, STEELE R, et al.Up-regulation of circulating miR-20a is correlated with hepatitis C virusmediated liver disease progression[J].Hepatology, 2013, 58 (3) :863-871.

[13] PADGETT KA, LAN RY, LAN RY, et al.Primary biliary cirrhosis is associated with altered hepatic microRNA expression[J].J Autoimmun, 2009, 32 (3-4) :246-253.

[14] QIAN Z, WANG HZ, FAN HJ, et al.MicroRNA profiling in T cells of peripheral blood mononuclear cell from patients with primary biliary cirrhosis[J].Natl Med J China, 2012, 92 (32) :2265-2267. (in Chinese) 钱铮, 汪怀周, 范华杰, 等.原发性胆汁性肝硬化患者外周血T细胞microRNA表达谱变化[J].中华医学杂志, 2012, 92 (32) :2265-2267.

[15]NIOMIYA M, KONDO Y, FUNAYAMA R, et al.Distinct of microRNAs expression profiles in primary biliary cirrhosis and evaluation of miR505-3P and miR197-3P as novel biomarkers[J].PLoS One, 2013, 8 (6) :e66086.

[16]CERMELLI S, RUGGIERI A, MARRERO JA, et al.Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease[J].PLoS One, 2011, 6 (8) :e23937.

[17]KRTZFELDT J, RAJEWSKY N, BRAICH R, et al.Silencing of microRNAs in vivo with‘antagomrs’[J].Nature, 2005, 438 (7068) :685-689.

[18] ESAU C, DAVIS S, MURRAY SF, et al.MiR-122 regulation of lipid metabolism revealed by in vivo antisense targeting[J].Cell Metab, 2006, 3 (2) :87-98.

[19] TRYNDYAK VP, LATENDRESSE JR, MONTGOMERY B, et al.Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a cholineand folate-deficient diet[J].Toxicol Appl Pharmacol, 2012, 262 (1) :52-59.

[20]WANG K, ZHANG S, MARZOLF B, et al.Circulating microRNAs, potential biomarkers for drug-induced liver injury[J].Proc Natl Acad Sci U S A, 2009, 106 (11) :4402-4407.

[21] STARKEY LEWIS PJ, DEAR J, PLATT V, et al.Circulating microRNAs as potential markers of human drug-induced liver injury[J].Hepatology, 2011, 54 (5) :1767-1776.

[22]BALA S, PETRASEK J, MUNDKUR S, et al.Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases[J].Hepatology, 2012, 56 (5) :1946-1957.

[23] MENG F, HENSON R, WEHBE-JANEK H, et al.microRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer[J].Gastroenterology, 2007, 133 (2) :647-658.

[24] TOMIMARU Y, EGUCHI H, NAGANO H, et al.Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma[J].J Hepatol, 2012, 56 (1) :167-175.

[25] QU KZ, ZHANG K, LI H, et al.Circulating microRNAs as biomarkers for hepatocellular carcinoma[J].J Clin Gastroenterol, 2011, 45 (4) :355-360.

[26]AQEILAN RI, CALIN JA, CROCE CM.miR-15a and miR-16-1 in cancer:discovery, function and future perspectives[J].Cell Death Differ, 2010, 17 (2) :215-220.

[27] GUO CJ, PAN Q, JIANG B, et al.Effects of upregulated expression of microRNA-16 on biological properties of culture-activated hepatic stellate cells[J].Apoptosis, 2009, 14 (11) :1331-1340.

[28]ZAHM AM, HAND NJ, BOATENG LA, et al.Circulating microRNA is a biomarker of biliary atresia[J].J Pediatr Gastroenterol Nutr, 2012, 55 (4) :366-369.引证本文:PENG XF, LIU HY.Research advances in circulating miRNAs for diagnosis of hepatobiliary diseases[J].J Clin Hepatol, 2014, 30 (9) :965-968. (in Chinese) 彭小芳, 刘海英.循环miRNA在肝胆疾病诊断中的研究进展[J].临床肝胆病杂志, 2014, 30 (9) :965-968.

Relative Articles

[1]	Xiuhong HUANG, Xiaoli XIE, Huiqing JIANG. Value of a microRNA risk score model in predicting the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(5): 1110-1115. doi: 10.3969/j.issn.1001-5256.2021.05.026
[2]	Huijun XIE, Nasot Rashed, Yong NING, Chuan GAO. Current status of research on circulating microRNAs as diagnostic markers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(2): 448-451. doi: 10.3969/j.issn.1001-5256.2021.02.042
[3]	Si ZHAO, Xueru WU, Linlin YIN, Lin MIAO, Guozhong JI, Xiuhua ZHANG. Value of SpyGlass single-operator choledochoscopy system in the diagnosis and treatment of patients with biliary tract diseases[J]. Journal of Clinical Hepatology, 2021, 37(10): 2395-2399. doi: 10.3969/j.issn.1001-5256.2021.10.027
[4]	Zeshan CHEN, Bin WEN, Peirong QIU, Hongni LAN, Baote HUANG, Xin DENG. Role of microRNA-122 in the development, progression, and diagnosis of liver disease[J]. Journal of Clinical Hepatology, 2021, 37(7): 1724-1728. doi: 10.3969/j.issn.1001-5256.2021.07.052
[5]	Liu LiLi, Su HeLing, Liu YongMing. Role of microRNA in hepatitis B virus infection-related diseases[J]. Journal of Clinical Hepatology, 2020, 36(3): 662-665. doi: 10.3969/j.issn.1001-5256.2020.03.041
[6]	Yin JingYang, Yang Kang. Nonsurgical treatment of malignant biliary obstructive diseases[J]. Journal of Clinical Hepatology, 2019, 35(3): 681-685. doi: 10.3969/j.issn.1001-5256.2019.03.052
[7]	Sun LiQi, Jin ZhenDong. Application of new endoscopic techniques in diagnosis of pancreaticobiliary diseases[J]. Journal of Clinical Hepatology, 2018, 34(3): 467-472. doi: 10.3969/j.issn.1001-5256.2018.03.003
[8]	Han MeiLin, Gong ZhenHua. Mechanism of action of gut microbiota in hepatobiliary diseases[J]. Journal of Clinical Hepatology, 2017, 33(2): 384-388. doi: 10.3969/j.issn.1001-5256.2017.02.040
[9]	Li PingYing, Yang YongGeng, Lu LunGen, Zhu ZhiYong, Wang YaPing, Ma YingCai. Value of microRNAs in diagnosis of chronic hepatitis B-related liver fibrosis[J]. Journal of Clinical Hepatology, 2017, 33(12): 2412-2415. doi: 10.3969/j.issn.1001-5256.2017.12.036
[10]	Wang QingLan, Tao YanYan, Lu: Jing, Liu Ping, Liu ChengHai. Antifibrotic mechanism of Fuzheng Huayu prescription by regulation of the differential expression of microRNAs in mouse liver[J]. Journal of Clinical Hepatology, 2016, 32(3): 503-508. doi: 10.3969/j.issn.1001-5256.2016.03.022
[11]	Qiu Hua, Sun XueHua, Zhou ZhenHua, Li Man, Zhang Xin, Gao YueQiu. Influence of interaction between endogenous miRNAs and hepatitis B virus in hepatocytes on hepatitis B virus transcription and related mechanisms[J]. Journal of Clinical Hepatology, 2016, 32(11): 2186-2190. doi: 10.3969/j.issn.1001-5256.2016.11.042
[12]	Wang DongXu, Huo TingTing, Tian YaoWen, Zhao Lei. Current status of research on microRNA associated with colorectal cancer liver metastasis[J]. Journal of Clinical Hepatology, 2016, 32(12): 2387-2390. doi: 10.3969/j.issn.1001-5256.2016.12.034
[13]	Zhang LiFen, Yu HongYu. Role of circulating microRNAs in development and progression of liver fibrosis[J]. Journal of Clinical Hepatology, 2016, 32(10): 2001-2003. doi: 10.3969/j.issn.1001-5256.2016.10.042
[14]	Cui DaPeng, Zhang YingChun, Gao ShuQuan, Han Lei, Zhang YiJun, Zhao LiJuan, Liu ZhenXian, Yang He. Value of serum carbohydrate antigens 19-9 and 24-2 in diagnosis of benign and malignant biliary tract diseases[J]. Journal of Clinical Hepatology, 2016, 32(7): 1364-1367. doi: 10.3969/j.issn.1001-5256.2016.07.033
[15]	Xiao ZuoHan, Meng Gang, Wang LiZhi, Sun WenJin. Diagnostic value of combined determination of DNA ploidy level and miRNA-21 expression in ascites cells for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(1): 93-98. doi: 10.3969/j.issn.1001-5256.2015.01.020
[16]	Lin Kun, Ci DanWangJiu, Chang ZhiHui, Liu ZhaoYu. Clinical value of circulating micro RNAs in hepatic,biliary and pancreatic carcinomas[J]. Journal of Clinical Hepatology, 2015, 31(5): 790-795. doi: 10.3969/j.issn.1001-5256.2015.05.040
[17]	Li Qiang, Zhuo QiBin, Huang YuXian, Chen Liang. Diagnosis and treatment of hepatocellular carcinoma from a new perspective of miRNAs[J]. Journal of Clinical Hepatology, 2015, 31(6): 977-981. doi: 10.3969/j.issn.1001-5256.2015.06.037
[18]	Qu YaChao, LYU Jun. Research progress in serum microRNA detection for diagnosis of hepatocellular carcinoma [J]. Journal of Clinical Hepatology, 2014, 30(3): 228-232. doi: 10.3969/j.issn.1001-5256.2014.03.008
[19]	Zhang RuLing, Lu LunGen. Current situation and future prospect of cholangiopathy[J]. Journal of Clinical Hepatology, 2012, 28(7): 481-483.
[20]	Zhang RuLing, Lu LunGen. Current research on the biliary tract diseases[J]. Journal of Clinical Hepatology, 2011, 27(9): 903-905+908.

Supplements(0)

Cited By

Cited by

Periodical cited type(3)

1.	李开楊，赵琦，黄敬，郭震凡，杨月月，石慧，杨梅. Th17/Treg平衡在非酒精性脂肪性肝病中的作用. 中国临床医生杂志. 2024(06): 638-641 .
2.	刘宇萌，安东. 淋巴细胞亚群检测在肾病综合征患儿免疫功能评价中的意义. 中华全科医学. 2022(04): 661-664+672 .
3.	肖丹，邓捷，金爱萍，欧妍. 枸橼酸钠对尿毒症血清诱导大鼠Th17/Treg失衡及氧化应激影响. 临床军医杂志. 2022(12): 1230-1233 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (2239) PDF downloads(583)

Research advances in circulating miRNAs for diagnosis of hepatobiliary diseases

DOI: 10.3969/j.issn.1001-5256.2014.09.032